InvestorsHub Logo
Followers 21
Posts 1400
Boards Moderated 0
Alias Born 03/03/2021

Re: biosectinvestor post# 505590

Tuesday, 08/16/2022 6:14:17 PM

Tuesday, August 16, 2022 6:14:17 PM

Post# of 692882
Saving Keytruda via reformulation I think is the Merck plan, not buying other companies.

There was an article about subcutaneous formulation a while back.
I recall a interview with a Merck rep who thought the reformulation was good enough for fresh patents. I don't have that interview, it's foggy memory, but I saw it.

The article from Fierce Bio is here.. https://www.fiercepharma.com/drug-delivery/merck-posts-early-clinical-data-subcutaneous-keytruda-setting-stage-for-further
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News